AZD4144 for Cardiovascular and Kidney Disease

This trial tests a new treatment called AZD4144 to evaluate its safety and effectiveness in individuals with heart and kidney problems. Researchers aim to understand how AZD4144 affects those with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). Participants will receive either AZD4144 or a placebo for 28 days. Individuals who experienced a heart attack or stroke more than two months ago and have chronic kidney issues may be suitable for this study.

As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that AZD4144 is being tested for safety and tolerability. In earlier studies, people with serious kidney and heart problems took AZD4144, and most did not experience major side effects. However, since this is an early stage of research, the main goal is to monitor for any side effects and understand how the body processes the drug. While the initial results appear promising, the researchers are still gathering complete safety information.¹²³⁴⁵

Researchers are excited about AZD4144 because it offers a new approach to treating cardiovascular and kidney diseases. Unlike standard treatments, which often focus on managing symptoms or slowing disease progression, AZD4144 targets the underlying mechanisms of these conditions. This drug works by modulating specific pathways involved in disease progression, potentially offering more effective and targeted results. This unique mechanism of action is promising because it might address the root causes rather than just the symptoms, providing a more comprehensive treatment option.

Research has shown that AZD4144 is under study for its potential to address heart and kidney problems. In this trial, participants will receive either AZD4144 or a placebo for 28 days. Although human studies have provided limited information so far, researchers are examining the drug's oral administration. The goal is for AZD4144 to positively affect heart disease caused by plaque buildup and chronic kidney disease. The main focus is currently on determining its safety and the body's response. Early studies are investigating the drug's action in the body, but more information is needed to confirm its efficacy.¹²³⁶⁷